Back to today’s briefing

Story perspectives

Eli Lilly Acquires Kelonia for $7 Billion CAR-T Therapy

4/20/2026

30 6 Full Breakdown

Summary

Lilly Expands Portfolio

Eli Lilly and Company finalized the Kelonia Therapeutics acquisition for up to $7 billion.
The deal includes $3.25 billion upfront and $3.75 billion in milestone payments.
Kelonia's KLN-1010 in vivo CAR-T targets relapsed multiple myeloma and aims to engineer T-cells inside the body.
The acquisition aligns with Lilly's strategy to diversify beyond obesity drugs and is expected to close in the second half of 2026, pending regulatory approvals.

History

Historical Context

The FDA's 2017 approval of Kymriah, the first CAR-T cell therapy for leukemia, marked a breakthrough in cancer treatment, building on decades of research into T cell manipulation since the 1980s. With an 83% remission rate in acute lymphoblastic leukemia patients, this innovation reflects a broader trend in the pharmaceutical industry, as seen in Eli Lilly's $7 billion acquisition of Kelonia Therapeutics for advanced cancer therapies.

1 of 2

Lilly Expands Portfolio

Eli Lilly and Company finalized the Kelonia Therapeutics acquisition for up to $7 billion.
The deal includes $3.25 billion upfront and $3.75 billion in milestone payments.
Kelonia's KLN-1010 in vivo CAR-T targets relapsed multiple myeloma and aims to engineer T-cells inside the body.
The acquisition aligns with Lilly's strategy to diversify beyond obesity drugs and is expected to close in the second half of 2026, pending regulatory approvals.

1 / 2